Endocrine Abstracts

Introduction: The treatment of prolactin adenomas is medical based on the use of dopaminergic agonists but the presence of an underlying valvulopathy makes the treatment by cabergoline delicate.

Clinical case: We report the case of a 60 year old female patient, operated on for aortic valve disease, with moderate mitral leakage. On the occasion of a decrease in visual acuity; a prolactin macro adenoma is diagnosed In agreement with the cardiologist; we opt for a treatment with quinagolide at progressive dose leading to a decrease of prolactin with especially an improvement of the visual disorders

Conclusion: The presence of valvulopathy in patients with prolactin macroadenoma may hinder the practitioner in his therapeutic choice; although it is considered less effective than cabergoline, quinagolide has allowed the decompression of the visual pathways and remains an alternative in valvulopathic patients at risk.